Research Article

Efficacy of Oxidized Regenerated Cellulose/Collagen Dressing for Management of Skin Wounds: A Systematic Review and Meta-Analysis

Li Zhang, Simei Wang, Meihua Tan, Hongwei Zhou, Ying Tang, and Yan Zou

1Department of Orthopedics and Trauma, The Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan, China
2Department of Wound Stoma Care, The Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan, China
3Department of Hand and Foot Surgery, The Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan, China

Correspondence should be addressed to Yan Zou; zy821008@sina.com

Received 13 July 2021; Accepted 22 July 2021; Published 4 August 2021

Academic Editor: Songwen Tan

Copyright © 2021 Li Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The purpose of this study was to evaluate the wound healing efficacy of oxidized regenerated cellulose (ORC)/collagen dressing and ORC/collagen/silver-ORC dressings compared to standard of care or control in treatment of chronic skin wounds such as diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure injuries sore ulcers (PISUs).

Methods. An electronic search was carried out in four popular databases PubMed, Scopus, Embase, and CENTRAL to identify thirteen included studies, comparing the clinical efficacy of ORC/collagen dressings when compared to control in management of chronic skin wounds, especially DFUs, VLUs, and PISUs, and skin graft donor site wounds. Results. Consolidated data from thirteen comparative clinical studies undertaken for management of DFUs, VLUs, and PISUs showed favorable outcomes towards use of ORC/collagen compared to other traditional and hydrocolloid foam dressings in terms of wound healing rate ($P = 0.02$) and percentage wound relative reduction ($P = 0.003$). The time taken to achieve complete wound healing in the included studies did not show any statistical significant difference ($P = 0.24$). There was no significant difference in adverse events between ORC/collagen-treated group and comparative group ($P = 0.19$). Conclusion. ORC/collagen wound dressings are beneficial in terms of improved wound healing rate and percentage wound relative reduction compared to already existing traditional standard of care with non-MMP, inhibiting biomaterials such as moistened gauze, autologous growth factors, hydrocolloid foam dressings, or ovine extracellular matrix.

1. Introduction

Wound is defined as a disruption in cutaneous structure and function, potentially involving underlying soft tissue [1]. Various factors that can result in impaired wound healing include aging, malnutrition, diabetes, vascular disease, and immunosuppression [2]. Chronic skin wounds occur when normal wound healing is dysregulated, resulting in a delay or arrest in one of the stages of wound healing. Prolongation of the inflammatory phase is the most common cause, usually due to wound infection or chronic irritation. Other possible mechanisms are tissue and wound hypoxia or failed epithelialization [3]. Surgeons sometimes reexcise the tissue and convert the chronic wound back into an acute one for faster healing and tissue regeneration [4]. The ultimate requirement for complete wound healing involves proper nursing of wound by application of wound dressings or wound care products [5]. The wound dressings used in management of chronic wounds needs to be cost-effective and clinically efficient, high patient acceptance, and most importantly improved patient’s quality of life [6].

Conventional wound dressings used for wound care management include traditional moistened gauze or petrolatum and modern dressings including alginates, hydrofibers, hydrogels, films, and biological agents including ovine collagen [7]. However, these dressings are permeable to bacteria and not conducive for creating a physiological environment. Nowadays, use of biological dressings like
collagen is impermeable to bacteria, thereby reducing colonization. The popularity of collagen dressing nowadays ought to its ease of application and being natural, non-immunogenic, nonpyrogenic, hypoallergenic, and pain-free healing [7]. Autologous platelet concentrates [8, 9] also have been beneficial and cost-effective in promoting wound healing.

Chronic wounds often present with elevated levels of matrix metalloproteinases (MMPs), which carry out proteolysis and inactivate the intrinsic growth factors involved in wound healing [10]. This may be the reason for which chronic skin wound takes longer time to heal [11]. The collagen dressings are found to inhibit the action of MMPs and encourage speedy deposition and proper organization of freshly formed collagen fibrils and granulation tissue formation, forming a bed to promote wound healing. These collagen fibrils undergo maturation and aid in epithelial migration from wound periphery for complete wound closure [12].

Oxidized regenerated cellulose (ORC)/collagen matrix is one such MMP inhibiting biomaterial which intensifies the wound healing environment by binding and inactivating excess levels of proteases and gelatinases in wound exudates [13]. Wu et al. [14] showed a statistical significant decrease in elastase, plasmin, and gelatinase activity in patients with venous leg ulcers (VLUs) treated with ORC/collagen matrix and also showed a significant and immediate reduction in protease activity in wound exudates from VLUs. Motzkau and also showed a significant and immediate reduction in protease activity in wound exudates from VLUs. Motzkau et al. in 2011 demonstrated the effects of MMP activity in the exudate of chronic diabetic foot ulcers (DFUs) treated with ORC/collagen dressing and found significantly decreased MMP-2 levels on day 5 of treatment [15].

Several studies have also assessed the efficacy of ORC/collagen dressing and ORC/collagen/silver-ORC dressings for wound management [16, 17]. However, to the best of our knowledge, no meta-analysis has been conducted till date proving the efficacy of ORC/collagen in different chronic skin wounds. Therefore, the purpose of this study was to evaluate the wound healing efficacy of ORC/collagen dressing and ORC/collagen/silver-ORC dressings compared to standard of care or control in the treatment of chronic skin wounds.

2. Methods

This systematic review and meta-analysis was carried out with strict adherence to preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines [18]. A prior protocol was framed to facilitate the smooth conduct in performing this systematic review.

2.1. Research Question. What is the wound healing efficacy of ORC/collagen dressing and ORC/collagen/silver-ORC dressings compared to standard of care or control in the treatment of chronic skin wounds? Patient or population (P): participants with chronic skin wounds (DFUs, VLUs, PIIs, etc.); intervention (I): wound dressing with ORC/collagen or ORC/collagen/silver-ORC dressings; comparison (C): standard of wound care or control; outcome (O): wound healing rate, wound reduction, time taken for complete healing, adverse events, etc.

2.2. Search Strategy. An electronic search was carried out in four popular databases PubMed, Scopus, Embase, and CENTRAL to identify potential eligible studies. The keywords used for the search strategy include collagen, oxidized regenerated cellulose, collagen/ORC wound dressing, wound healing, chronic skin wounds, diabetic foot ulcer, venous leg ulcer, and pressure injuries. The keywords were combined in the advanced search using Boolean operators. Additionally, a manual search was also performed in published issues of Advances in Skin and Wound Care, Journal of Wound Care, International Wound Journal, Wounds, and International Journal of Lower Extremity Wounds. The bibliography section of the potentially eligible studies and previously performed systematic reviews was also inspected for any relevant studies. No restriction in publication year and language was applied. The search results from different electronic databases and manual search were imported to a citation manager (endnote) to remove duplicates and subsequently subjected to assessment for study selection.

2.3. Study Selection. The retrieved studies were subjected to title and abstract screening by two independent reviewers based on relevancy. The relevant articles were then assessed by retrieving full text for each of the potentially eligible studies. The criteria for inclusion of studies are as follows:

(1) Comparative clinical studies
(2) Application of ORC/collagen or ORC/collagen/silver-ORC dressings compared to control in management of chronic skin wounds (DFUs, VLUs, PIIs, etc.)
(3) Studies with minimum sample size of 10 (5 per group)

The case reports, case series, cohort studies, and clinical studies assessing another MMP inhibiting dressing with ORC/collagen dressing were excluded. The reasons of exclusion of the eligible studies were also provided. Any disagreement between the two reviewers with regard to study selection and exclusion was resolved by consensus with a third reviewer.

2.4. Data Extraction. The data extraction from the included trials was carried out by two independent reviewers using an excel spreadsheet. The demographic data of participants such as age, gender, type and duration of wound, and wound area and size; interventional characteristics such as type of wound dressing, change of dressing per week, and follow-up; and outcome variables such as wound closure, percentage of wound relative reduction, time taken for complete epithelialization and granulation tissue formation, and adverse events were recorded for each included trial. In case of any missing or unclear data, the authors were contacted via e-mail to seek out clarifications.
2.5. Data Synthesis. The data extracted from the included trials were subjected to both qualitative and quantitative analysis. The demographic data and interventional characteristics along with certain outcomes with little similarities were qualitatively analyzed and tabulated for better representation. The qualitative analyses of the similar outcome assessment were carried out using meta-analysis. The meta-analysis was performed by using R 3.5.1. The heterogeneity among the studies was calculated using $\chi^2$ and $I^2$ statistics. A random or fixed effect model for meta-analysis was employed based on the $I^2$ value. $I^2$ of less than 40% was considered unimportant while that of more than 40% was viewed as moderate to considerable heterogeneity.

2.6. Risk of Bias Assessment. The risk of bias analysis was carried out using Cochrane risk of bias tool [19] by two independent reviewers. The included trials were analyzed for bias in selection of participants by evaluating randomization process and allocation concealment methods; bias in blinding of participants and personnel; bias in blinding of outcome assessor; and bias in selective reporting of results and lost to follow-up. The studies were graded as low, moderate, and high risk based on adequacy of the above-mentioned domains.

3. Results

3.1. Search Results. This systematic review assessed the data from 13 included studies [13, 15, 20–30] comparing the clinical efficacy of ORC/collagen dressings when compared to control in the management of chronic skin wounds, especially DFUs, VLUs, and PI s. The electronic search was carried out in all 4 databases and the manual search retrieved 699 articles, where the total studies identified were 545 after removal of duplicates. After careful title and abstract screening, only eighteen studies were found potentially eligible and relevant. Full text evaluations of eighteen studies were carried out to find only thirteen studies satisfying the inclusion criteria. The rest of the five studies were excluded and detailed reasons of exclusion were provided. The study selection and exclusion process is depicted in Figure 1.

3.2. Demographic and Intervventional Characteristics. There were 10 randomized clinical trials [13, 15, 21, 22, 24–27, 29, 30], 2 comparative clinical trials [23, 28], and 1 comparative retrospective study [20], comparing the use of ORC/collagen dressings and other wound dressings as control. 8 included studies [15, 22–24, 26–29] assessed the effect of ORC/collagen on healing of DFUs, 2 studies [13, 21] evaluated healing of VLUs, 1 study [25] evaluated healing of PI s, and another study assessed healing of skin graft donor site wounds. A consolidated total of 1538 wounds were evaluated in 13 included studies [13, 15, 20–30]. Out of which, 782 wounds were treated with ORC/collagen dressing and rest of 736 wounds were treated either with standard wound care, moistened gauze, hydrocolloid foam, or ovine-based extracellular matrix. The age range of the patients presented with chronic skin wounds is from 18 to 88 years.

3.3. Meta-Analysis. The quantitative analysis for the outcomes was carried out by meta-analyzing the data only if more than 2 similar studies were found to report a similar outcome with a common unit of measurement. The meta-analysis was performed for the following parameters.

3.3.1. Wound Healing Rate. Six studies [21–23, 27, 29, 30] were analyzed to compare the wound healing rate between the ORC/collagen group and control group. The overall OR 1.79 [1.09, 2.94] was found to be significantly favoring ORC/collagen-treated group ($P = 0.02$). The heterogeneity among the studies was found to be moderate ($I^2 = 57\%$), as shown in Figure 2.

3.3.2. Time to Achieve Complete Wound Healing. Only three studies [21, 25, 28] were analyzed to compare the time to achieve complete wound healing between the ORC/collagen group and control group. The overall MD $-2.25 [-22.95, 18.46]$ between both groups was found nonsignificant ($P = 0.83$). The heterogeneity among the studies was also found to be high ($I^2 = 97\%$), as shown in Figure 3.

3.3.3. Percentage Wound Relative Reduction. Only three studies [21, 25, 28] were analyzed to compare the percentage wound relative reduction between the ORC/collagen group and control group. The overall MD $18.15 [6.09, 30.21]$ was found to be significantly favoring ORC/collagen-treated group ($P = 0.003$). The heterogeneity among the studies was also found to be low ($I^2 = 29\%$), as shown in Figure 4.

3.3.4. Adverse Events in Wound Healing. Four studies [21, 22, 29, 30] were analyzed to compare the adverse events in wound healing between the ORC/collagen group and control group. The overall RD $-0.08 [-0.21, 0.04]$ between both groups was found nonsignificant ($P = 0.19$). The heterogeneity among the studies was also found to be moderate ($I^2 = 54\%$), as shown in Figure 5.

3.4. Risk of Bias Assessment. The included studies were assessed to have low to moderate risk of bias, except 2 studies [15, 23], which were assessed as high risk due to lack in randomization and blinding of outcome assessor, respectively, as shown in Figure 6.
Records identified through database searching \((n = 697)\)

Additional records identified through other sources \((n = 2)\)

Records after duplicates removed \((n = 545)\)

Records screened \((n = 545)\)

Records excluded \((n = 527)\)

Full-text articles assessed for eligibility \((n = 18)\)

Full-text articles excluded with reasons \((n = 5)\)
- Cohort studies = 3
- Case series = 2

Studies included in qualitative synthesis \((n = 13)\)

Studies included in quantitative synthesis (meta-analysis) \((n = 8)\)

**Figure 1:** PRISMA flow chart showing study selection process.

**Table 1:** Demographic data of all included studies.

| Authors                     | Study design | Centres | No. of patients | Age          | Gender (M/F) | Test dressing                                      | Control dressing                                      | Type of wound |
|-----------------------------|--------------|---------|-----------------|--------------|--------------|---------------------------------------------------|-------------------------------------------------------|---------------|
| Veves et al., 2002 [29]     | RCT          | 11      | 276             | 58.3 (23–85) | 203/73       | ORC/collagen matrix                               | Gauze                                                 | DFUs          |
| Vin et al., 2002 [30]       | RCT          | 14      | 73              | 33–88        | 26/47        | ORC/collagen matrix                               | Nonadherent dressing (Adaptic)                        | VLUs          |
| Lobmann et al., 2006 [26]   | RCT          | 1       | 33              | 64 ± 11      | NR           | ORC/collagen matrix                               | Good standard wound care                              | DFUs          |
| Luis Lazaro-Martinez et al., 2007 [27] | RCT          | 1       | 40              | NR           | NR           | ORC/collagen matrix                               | Hydroactive dressing                                  | DFUs          |
| Kakagia et al., 2007 [24]   | RCT          | 1       | 54              | NR           | 22/29        | ORC/collagen matrix                               | Autologous growth factors                             | DFUs          |
| Smeets et al., 2008 [13]    | RCT          | NR      | 27              | 63 ± 8       | NR           | ORC/collagen matrix                               | Hydro-colloid dressing                                | VLUs          |
| Motzkau et al., 2010 [15]   | RCT          | 1       | 19              | NR           | NR           | ORC/collagen matrix                               | Good standard wound care                              | DFUs          |
| Ulrich et al., 2011 [28]    | CCT          | 1       | 32              | >18          | 22/10        | ORC/collagen matrix                               | Open wound healing                                    | DFUs          |
| Gottrup et al., 2013 [22]   | RCT          | 2       | 39              | NR           | 35/4         | ORC/collagen/silver-ORC                           | Foam hydropolymer dressing                            | DFUs          |
| Kloeters et al., 2015 [25]  | RCT          | 1       | 33              | >18          | NR           | ORC/collagen with foam dressing                    | Standard of care                                      | VLUs          |
| Cullen et al., 2017 [21]    | RCT          | 3       | 49              | 24–90        | 31/18        | ORC/collagen/silver-ORC                           | Standard of care                                      | VLUs          |
4. Discussion

This systematic review aimed at evaluating the wound healing efficacy and adverse events associated with ORC/collagen dressings in treatment of various chronic skin wounds. Consolidated data from thirteen comparative clinical studies undertaken for management of DFUs, VLUs, and PIs showed favorable outcomes towards use of ORC/collagen compared to other traditional and hydrocolloid foam dressings in terms of wound healing rate and percentage wound relative reduction. The time taken to achieve complete wound healing in the included studies did not show any statistical significant difference. There was no significant difference in adverse events between ORC/collagen-treated group and comparative group ($P = 0.19$).

The beneficial effect of ORC/collagen can be due to its ability to absorb oxygen free radicals, bind excess iron, and protect growth factors present in chronic wound fluid [31]. The above mechanism may explain how ORC/collagen can redress the imbalance of the chronic wound environment and therefore may have a beneficial effect in the treatment of chronic skin wounds.

### Table 1: Interventional characteristics of all included studies.

| Authors                          | Type of wound | Wound duration | Wound area, test | No. of test wounds | No. of control wounds | No. of dressing changes per week per patient, test | No. of dressing changes per week per patient, control | Follow-up |
|----------------------------------|---------------|----------------|------------------|--------------------|-----------------------|---------------------------------------------------|-----------------------------------------------------|-----------|
| Veves et al., 2002 [29]          | DFUs          | <6 and >6 months | 2.5 (0.2–27.4)   | 138                | 138                   | 10.1                                              | 11.2                                               | 12 weeks  |
| Vin et al., 2002 [30]            | VLUs          | NR             | NR               | 37                 | 36                    | 3.9 + 1.4 d                                       | 4.1 + 1.6 d                                       | 12 weeks  |
| Lobmann et al., 2006 [26]        | DFUs          | NR             | 1237 mm sq       | 18                 | 15                    | Daily                                             | Daily                                              | 1 week    |
| Luis Lazaro-Martinez et al., 2007 [27] | DFUs        | NR             | NR               | 20                 | 20                    | Every 2 days                                      | Every 2 days                                      | 6 weeks   |
| Kakagia et al., 2007 [24]        | DFUs          | ≥3 months      | 25.8 ± 15.2      | 17                 | 17                    | NR                                                | NR                                                 | 8 weeks    |
| Smeets et al., 2008 [13]         | VLUs          | NR             | NR               | 17                 | 10                    | NR                                                | NR                                                 | 8 weeks    |
| Motzkau et al., 2010 [15]        | DFUs          | NR             | NR               | 12 ± 6             | 14 ± 5                | NR                                                | NR                                                 | 5 days     |
| Ulrich et al., 2011 [28]         | DFUs          | NR             | 2.1 ± 3.1 cm sq  | 24                 | 15                    | NR                                                | NR                                                 | 12 weeks   |
| Gottrup et al., 2013 [22]        | DFUs          | ≥6 weeks       | More than 1 cm sq| 23                 | 10                    | 2–3 days                                          | 2–3 days                                           | 12 weeks   |
| Kloeters et al., 2015 [25]       | PIs           | <12 and >12 months | 6.9 ± 4.1       | 22                 | 27                    | Twice in a week                                   | Twice in a week                                    | 12 weeks   |
| Cullen et al., 2017 [21]         | VLUs          | NR             | 1.5 cm sq        | 22                 | 27                    | Once in 2 weeks                                   | Once in 2 weeks                                    | 16 weeks   |
| Griffin et al., 2019 [23]        | DFUs          | NR             | 69.67 ± 9.45     | 29                 | 30                    | 1.79 ± 0.73                                       | 0.67 ± 0.66                                       | NR        |
| Chowdhry, 2019 [20]              | Skin graft donor site wounds | NR             | 69.13 ± 6.81     | 29                 | 30                    |                                                   |                                                    |           |

Note: DFU, diabetic foot ulcer; VLU, venous leg ulcer; PI, pressure injury; NR, not reported.

### Table 2: Interventional characteristics of all included studies.

| Authors                          | Study design | Centres | No. of patients | Age | Gender (M/F) | Test dressing | Control dressing | Type of wound |
|----------------------------------|--------------|---------|-----------------|-----|--------------|---------------|------------------|---------------|
| Griffin et al., 2019 [23]        | CCT          | 1       | 844             | NR  | NR           | ORC/collagen/collagen extracellular matrix | Ovine (sheep-derived) collagen extracellular matrix | DFUs         |
| Chowdhry, 2019 [20]              | CRS          | 1       | 59              | 51.9 ± 14.4 | 27/32 | ORC/collagen/silver-ORC | Petrolatum-based gauze dressing | Skin graft donor site wounds |

Note: RCT, randomized clinical trial; CCT, comparative clinical trial; CRS, comparative retrospective study; ORC, oxidized regenerated cellulose; DFU, diabetic foot ulcer; VLU, venous leg ulcer; PI, pressure injuries; NR, not reported.
| Study or subgroup | ORC/collagen | Control | Weight (%) | Odds ratio M-H, random, 95% CI | Year |
|------------------|--------------|---------|------------|-----------------------------|------|
| Vin 2002         | 18/37        | 12/36   | 15.4       | 1.89 [0.74, 4.88]           | 2002 |
| Veeves 2002      | 51/138       | 37/138  | 25.5       | 1.60 [0.96, 2.67]           | 2002 |
| Lazaro-Martinez 2007 | 12/19        | 3/19    | 8.0        | 9.14 [1.95, 42.90]          | 2007 |
| Gottrup 2013     | 12/33        | 4/33    | 10.7       | 4.14 [1.17, 14.65]          | 2013 |
| Cullen 2017      | 14/22        | 22/27   | 10.3       | 0.40 [0.11, 1.46]           | 2017 |
| Griffin 2019     | 346/422      | 315/422 | 30.2       | 1.55 [1.11, 2.15]           | 2019 |
| Total (95% CI)   | 671/675      | 100.0   | 1.79 [1.09, 2.94] |

Heterogeneity: $\tau^2 = 307.47$; $\chi^2 = 77.48$, df = 2 ($P < 0.00001$); $I^2 = 97\%$

Test for overall effect: $Z = 0.21$ ($P = 0.83$)

**Figure 2:** Forest plot showing comparison of complete wound healing rate between ORC/collagen and control groups.

| Study or subgroup | ORC/collagen | Control | Weight (%) | Mean difference IV, random, 95% CI | Year |
|------------------|--------------|---------|------------|-----------------------------------|------|
| Vin 2002         | 65.9/23.9    | 63.8/25.2 | 12/10    | 28.5/36.2 | 2.10/28.5 [−15.93, 20.13] | 2002 |
| Veeves 2002      | 49/2.8       | 40/2.8   | 37/10     | 36.2/36.2 | 9.00/36.2 [7.81, 10.19]  | 2002 |
| Lazaro-Martinez 2007 | 23.3/9.9     | 12/40.6  | 3/11      | 35.3/22    | −17.30/22.5 [−23.05, −11.55] | 2007 |
| Total (95% CI)   | 81/52        | 100.0    | −2.25/22.95 [−22.95, 18.46] |

Heterogeneity: $\tau^2 = 307.47$; $\chi^2 = 77.48$, df = 2 ($P < 0.00001$); $I^2 = 97\%$

Test for overall effect: $Z = 0.21$ ($P = 0.83$)

**Figure 3:** Forest plot showing comparison of time taken to achieve complete wound healing between ORC/collagen and control groups.

| Study or subgroup | ORC/collagen | Control | Weight (%) | Odds ratio M-H, random, 95% CI | Year |
|------------------|--------------|---------|------------|-----------------------------|------|
| Cullen 2017      | 45/26        | 22/40   | 10/10     | 23.6/36.2 | 5.00/23.6 [−16.54, 26.54] | 2017 |
| Kloeters 2015    | 65/13        | 23/41   | 11/10     | 63.9/36.2 | 24.00/36.2 [−15.36, 32.64] | 2017 |
| Ulrich 2011      | 85.6/28.6    | 22/72.5 | 27/12     | 77.8/36.2 | 13.10/77.8 [−18.59, 44.79] | 2017 |
| Total (95% CI)   | 67/47        | 100.0   | 18.15/100.0 [6.09, 30.21] |

Heterogeneity: $\tau^2 = 307.47$; $\chi^2 = 77.48$, df = 2 ($P < 0.00001$); $I^2 = 97\%$

Test for overall effect: $Z = 0.21$ ($P = 0.83$)

**Figure 4:** Forest plot showing comparison of percentage wound relative reduction between ORC/collagen and control groups.

| Study or subgroup | ORC/collagen | Control | Weight (%) | Risk difference M-H, random, 95% CI | Year |
|------------------|--------------|---------|------------|-----------------------------------|------|
| Vin 2002         | 3/37         | 5/36    | 30.0       | −0.06/30.0 [−0.20, 0.09]        | 2002 |
| Veeves 2002      | 37/138       | 34/138  | 36.9       | 0.02/30.0 [−0.08, 0.12]        | 2002 |
| Gottrup 2013     | 0/23         | 4/13    | 16.6       | −0.31/16.6 [−0.56, −0.06]     | 2013 |
| Cullen 2017      | 5/22         | 10/27   | 16.5       | −0.14/16.5 [−0.40, 0.11]      | 2017 |
| Total (95% CI)   | 220/214      | 100.0   | −0.08/100.0 [−0.21, 0.04] |

Total events 45/53

Heterogeneity: $\tau^2 = 0.01$; $\chi^2 = 6.48$, df = 3 ($P = 0.09$); $I^2 = 54\%$

Test for overall effect: $Z = 1.13$ ($P = 0.19$)

**Figure 5:** Forest plot showing comparison of adverse events in wound healing between ORC/collagen and control groups.
Figure 6: Risk of (a) bias summary and (b) bias graph of all included studies.
It is proven that there exists a complex intrinsic interaction between cells and its mediators in response to tissue injury. Wounds that do not progress beyond the inflammatory phase often demonstrate an increased activity of proteases such as MMPs and elastase, as well as the persistence of inflammatory cells [32]. There is also a downregulation of tissue inhibitor of matrix metalloproteinase activity. In particular, the inflammatory response seems to be high in chronic skin wounds, characterized by increased levels of proinflammatory cytokines and proteases [33]. While controlling levels of inflammation and protease expression is a critical part of normal wound healing, elevated and prolonged expression of proteases produced during the inflammatory phase of healing can lead to excessive ECM degradation associated with impaired healing [11]. Therefore, use of a collagen-based MMP inhibiting biomaterial as wound dressing has been popular nowadays.

The protease inhibitory role of ORC/collagen is well established in many in vitro and in vivo studies. Smeets et al. in 2008 [13] showed that the patients treated with ORC/collagen matrix showed a significant decrease in elastase, plasmin, and gelatinase activity as compared with the control group, with no significant difference in the MMP-2 concentrations between the two groups. However, the results showed a significant and immediate reduction in protease activity in wound exudates from VLUs treated with ORC/collagen.

Apart from this, ORC/collagen was also found to promote fibroblast migration and proliferation in vitro [34]. The in vivo effects of ORC/collagen on wound of diabetic mice were also investigated in terms of wound closure and histological analysis and concluded that the ORC/collagen accelerated wound closure and histological appearance by promoting fibroblastic activity and thereby supporting complete epithelialization [34]. This could be a reason which could explain our favorable results towards ORC/collagen dressing in terms of faster wound healing rate and improved percentage wound relative reduction. However, no significant difference was noted in the time to complete wound closure between ORC/collagen and comparative dressings. Indeed, complete wound healing does not often require just one dressing and at the reepithelialization stage or when exudate disappears, the dressing needs to be discontinued. This is an important reason for the nonsignificant difference between the two groups of our review.

Many of the included studies [13, 15, 24–26] in this review estimated the protease, elastase, and other MMP levels in the wound exudates and compared between the ORC/collagen-treated wounds and other traditional or biologically dressed wounds. The comparison of anti-MMP activity of ORC/collagen was however out of the scope of this review. Our review only analyzed the wound healing efficacy and, to certain level, the safety profile of using ORC/collagen over other controls.

It was also noted that the patients treated with ORC/collagen required less changes in dressing per week per patient. However, a quantitative analysis could not be performed due to lack of similar data representation. There was no significant difference observed in adverse events or complications associated with ORC/collagen dressings compared to controls. The adverse events associated with the dressing included infections, septicemia, and failure in granulation bed formation. The extent of adverse events observed with use of ORC/collagen and silver-ORC/collagen was similar to that of the materials used as controls for wound healing.

The moderate to high heterogeneity among the studies analyzing time to achieve complete healing, healing rate, and adverse events could be explained by the fact that there had been variation in systemic status of the patients, wound size and duration, and follow-up period. The diabetic foot ulcers are difficult to heal compared to other chronic skin wounds due to intrinsic impairment of wound healing response [35]. The limitation of this review includes difficulty in conducting subgroup analysis based on type of wounds (DFUs, VLUs, PI’s, etc.) and between silver-ORC and ORC/collagen dressing, due to lack of sufficient studies.

### 5. Conclusions

ORC/collagen wound dressings are beneficial in terms of improved wound healing rate and percentage wound relative reduction compared to already existing traditional standard of care with non-MMP, inhibiting biomaterials such as traditional moistened gauze or petrolatum and modern dressings including foams, alginates, hydrofibers, hydrogels, hydrocolloids, films, and biological agents such as ovine collagen. Future comparative studies of high quality evidence are required to further establish the beneficial and protective effect of ORC/collagen dressings in the treatment of chronic skin wounds.

### Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Acknowledgments

This study was supported by the Project of Hunan Education Department (20C1586) "Study of Diabetic Foot Wounds Exudate Proteomics and Its Application in "DAVIC Medical Sterilizing Liquid Dressing” Mechanism Research."

### References

[1] J. Larouche, S. Sheoran, K. Maruyama, and M. M. Martino, "Immune regulation of skin wound healing: mechanisms and novel therapeutic targets," *Advances in Wound Care*, vol. 7, no. 7, pp. 209–231, 2018.

[2] K. Anderson and R. L. Hamm, "Factors that impair wound healing," *Journal of the American College of Clinical Wound Specialists*, vol. 4, no. 4, pp. 84–91, 2014.

[3] S. A. Eming, T. Krieg, and J. M. Davidson, "Inflammation in wound repair: molecular and cellular mechanisms," *Journal of Investigative Dermatology*, vol. 127, no. 3, pp. 514–525, 2007.

[4] C. Theoret, "Physiology of wound healing," *Equine Wound Management*, vol. 2016, pp. 1–13, 2016.

[5] G. Dabiri, E. Damstetter, and T. Phillips, "Choosing a wound dressing based on common wound characteristics," *Advances in Wound Care*, vol. 5, no. 1, pp. 32–41, 2016.
Evidence-Based Complementary and Alternative Medicine

[6] R. G. Frykberg and J. Banks, “Challenges in the treatment of chronic wounds,” Advances in Wound Care, vol. 4, no. 9, pp. 560–582, 2015.

[7] O. Singh, S. Gupta, M. Soni, S. Moses, S. Shukla, and R. Mathur, "Collagen dressing versus conventional dressings in burn and chronic wounds: a retrospective study," Journal of Cutaneous and Aesthetic Surgery, vol. 4, no. 1, pp. 12–16, 2011.

[8] M. Del Fabbro, L. Karanxha, S. Panda, C. Bucchi, J. N. Doraissamy, and M. Sankari, "Autologous platelet concentrates for treating periodontal intrafibrinoy defects," Cochrane Database Syst Rev, vol. 11, Article ID CD011423, 2018.

[9] M. Del Fabbro, L. Karanxha, S. Panda, C. Bucchi, J. N. Doraissamy, and M. Sankari, “Autologous platelet concentrates for treating periodontal intrafibrinoy defects,” Cochrane Database Syst Rev, vol. 11, Article ID CD011423, 2018.

[10] S. M. McCarty and S. L. Percival, "Proteases and delayed wound healing," Advances in Wound Care, vol. 4, no. 4, pp. 225–234, 2015.

[11] R. G. Frykberg and J. Banks, "Challenges in the treatment of chronic wounds," Advances in Wound Care, vol. 4, no. 9, pp. 560–582, 2015.

[12] C. A. Fleck and R. Simman, "Modern collagen wound dressings: function and purpose," The Journal of the American College of Certified Wound Specialists, vol. 2, no. 3, pp. 50–54, 2011.

[13] R. Smeets, D. Ulrich, F. Unglaub, M. Wölte, and N. Pallua, "Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration," International Wound Journal, vol. 5, no. 2, pp. 195–203, 2008.

[14] S. Wu, A. J. Applewhite, J. Niegzoda, J. Niegzoda, and R. Snyder, "Oxidized regenerated cellulose/collagen dressings: review of evidence and recommendations," Advances in Skin & Wound Care, vol. 30, no. 11, pp. S1–S18, 2017.

[15] M. Motzkau, J. Tautenhahn, H. Lehnert, and R. Lobmann, "Expression of matrix-metalloproteases in the fluid of chronic diabetic foot wounds treated with a protease absorbent dressing," Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association, vol. 119, no. 5, pp. 286–290, 2011.

[16] G. Chicone, V. F. de Carvalho, and A. O. Paggiaro, "Use of oxidized regenerated cellulose/collagen matrix in chronic diabetic foot ulcers: a systematic review," Advances in Skin & Wound Care, vol. 31, no. 2, pp. 66–71, 2018.

[17] J. Bisemond, M. Augustin, M. Dietlein et al., "Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review," Journal of Wound Care, vol. 29, no. 2, pp. 102–118, 2020.

[18] A. Liberati, D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gotzsche, and J. Ioannidis, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration," BMJ-British Medical Journal, vol. 339, 2009.

[19] J. P. T. Higgins, D. G. Altman, P. C. Gotzsche, P. Jüni, D. Moher, and A. D. Oxman, "The cochrane collaboration’s tool for assessing risk of bias in randomised trials," BMJ-British Medical Journal, vol. 99, p. 343, 2011.

[20] A. Chowdhry, "Use of oxidized regenerated cellulose (ORC)/collagen/silver-ORC dressings to help manage skin graft donor site wounds," JPRAS Open, vol. 22, pp. 33–40, 2019.

[21] B. M. Cullen, T. E. Serena, M. C. Gibson, R. J. Snyder, J. R. Hanif, and R. A. Yaakov, "Randomized controlled trial comparing collagen/oxidized regenerated cellulose/silver to standard of care in the management of venous leg ulcers," Advances in Skin & Wound Care, vol. 30, no. 10, pp. 464–468, 2017.

[22] J. D. Gogtrup, B. M. Cullen, T. Karlsmark, M. Bischoff-Mikkelsen, L. Nisbet, and M. C. Gibson, "Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment," Wound Repair and Regeneration, vol. 21, no. 2, pp. 216–225, 2013.

[23] L. Griffin, M. J. Carter, R. D’Agostino, and L. D’Agostino McGowan, "Comparative effectiveness of two collagen-containing dressings: oxidized regenerated cellulose (ORC)/Collagen/Silver-ORC dressing versus ovine collagen extra-cellular matrix," Wounds: A Compendium of Clinical Research and Practice, vol. 31, no. 11, pp. E73–E76, 2019.

[24] D. D. Kakagia, K. J. Kazakos, K. C. Xarchas et al., “Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial,” Journal of Diabetes and Its Complications, vol. 21, no. 6, pp. 387–391, 2007.

[25] O. Kloeters, F. Unglaub, E. de Laat, M. van Abeelen, and D. Ulrich, "Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose/collagen matrix treatment in pressure sore ulcers," International Wound Journal, vol. 13, no. 6, pp. 1231–1236, 2016.

[26] R. Lobmann, C. Zemlin, M. Motzkau, K. Reschke, and H. Lehnert, “Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing,” Journal of Diabetes and Its Complications, vol. 20, no. 5, pp. 329–335, 2006.

[27] J. Luis Lázaro-Martínez, E. García-Morales, J. V. Benet-Montesinos, F. R. Martinez-De-Jesús, and F. Javier Aragón-Sánchez, "Estudio aleatorizado y comparativo de un apósito de colágeno y celulosa oxidada regenerada en el tratamiento de úlceras neuropáticas de pie diabético," Cirugía Española, vol. 82, no. 1, pp. 27–31, 2007.

[28] D. Ulrich, R. Smeets, F. Unglaub, M. Wölte, and N. Pallua, "Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with diabetic foot ulcers," Journal of Wound, Ostomy & Continence Nursing, vol. 38, no. 5, pp. 522–528, 2011.

[29] A. Veves, P. Sheehan, and H. T. Pham A, "A randomized, controlled trial of promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers," Archives of Surgery, vol. 137, no. 7, pp. 822–827, 2002.

[30] F. Vin, L. Teot, and S. Meaume, "The healing properties of Promogran in venous leg ulcers," Journal of Wound, Care, vol. 11, no. 9, pp. 335–341, 2002.

[31] B. Cullen, P. W. Watt, C. Lundqvist et al., "The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action," The International Journal of Biochemistry & Cell Biology, vol. 34, no. 12, pp. 1544–1556, 2002.

[32] D. J. Leaper, G. Schultz, K. Carville, J. Fletcher, T. Swanson, and R. Drake, "Extending the TIME concept: what have we learned in the past 10 years?" International Wound Journal, vol. 9, no. s2, pp. 1–19, 2012.

[33] R. Zhao, H. Liang, E. Clarke, C. Jackson, and M. Xue, "Inflammation in chronic wounds," International Journal of Molecular Sciences, vol. 17, no. 12, 2016.

[34] J. Hart, D. Silcock, S. Gunigle, B. Cullen, N. D. Light, and P. W. Watt, "The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology"
and in vivo in a model of compromised healing.” *The International Journal of Biochemistry & Cell Biology*, vol. 34, no. 12, pp. 1557–1570, 2002.

[35] R. G. Frykberg and J. Banks, “Management of diabetic foot ulcers: a review.” *Federal Practitioner: For the Health Care Professionals of the VA, DoD, and PHS*, vol. 33, no. 2, pp. 16–23, 2016.